Home Industry Systemic Bio nominated as a finalist for the SLAS Innovation Award 2025

Systemic Bio nominated as a finalist for the SLAS Innovation Award 2025

Systemic Bio, a subsidiary of 3D Systems, has made it into the top 10 of the prestigious SLAS Innovation Award 2025 with its h-VIOS platform. Each year, the award recognizes technological innovations that have the potential to fundamentally influence laboratory science and automation. Systemic Bio’s platform enables the production of complex, vascularized tissue models using advanced bioprinting technology.

The h-VIOS platform aims to make drug development more efficient and predictable through the use of bioprinted tissues that accurately replicate human organ systems.

“We are thrilled to be recognized by SLAS as a Top 10 Finalist for their esteemed Innovation Award,” said Taci Pereira, CEO of Systemic Bio. “This acknowledgment reflects the hard work and ingenuity of our team and highlights the transformative power of our platform in driving innovation within the pharmaceutical industry. By providing more accurate and predictive tools, we aim to accelerate the development of safer and more effective therapies for patients worldwide.”

The tissue models are manufactured in a state-of-the-art facility in Houston, which is equipped with an ISO 7 clean room and a comprehensive quality management system (QMS). Production capacity includes thousands of models that are used for internal research as well as for collaborations with leading pharmaceutical companies.

The significance of the platform lies in its ability to revolutionize preclinical testing by overcoming the limitations of conventional methods. Conventional tests on animal models often provide inadequate results for predicting human responses. The tissues developed by Systemic Bio offer a more accurate and efficient alternative that could reduce both time and costs in drug development.

Systemic Bio will present the platform at the SLAS conference in San Diego. The winner of the Innovation Award will be announced on January 29, 2025. The nomination puts the company in the spotlight of the scientific community and the pharmaceutical industry.


Subscribe to our Newsletter

3DPresso is a weekly newsletter that links to the most exciting global stories from the 3D printing and additive manufacturing industry.

Privacy Policy*
 

You can find the privacy policy for the newsletter here. You can unsubscribe from the newsletter at any time. For further questions, you can contact us here.